New antibody GEN3018 enters first human tests for tough blood cancers
NCT ID NCT07384715
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. The main goal is to check safety and find the right dose. Up to 78 participants will receive the drug by IV, and the study will monitor them closely for side effects and any signs that the drug is working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GEN3018 (an antibody given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat blood cancers like AML and MDS.
What could go wrong
This is a very early, first-in-human trial focused on safety, not effectiveness. The drug may not work or could have serious side effects. Only 78 people will be enrolled, so results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus Universitetshospital - Skejby
RECRUITINGAarhus, 8200, Denmark
-
Charite Campus Virchow-Klinikum
NOT_YET_RECRUITINGBerlin, Germany
-
Copenhagen Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
-
Hospital Clínic de Barcelona
NOT_YET_RECRUITINGBarcelona, 08036, Spain
-
Hospital Universitari Vall d'Hebron
NOT_YET_RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitari i Politècnic La Fe
RECRUITINGValencia, 46026, Spain
-
Hospital Universitario 12 de Octubre
NOT_YET_RECRUITINGMadrid, 28041, Spain
-
Klinikum der Universität München Großhadern
NOT_YET_RECRUITINGMunich, Germany
-
Universitätsklinikum Carl Gustav Carus Dresden
NOT_YET_RECRUITINGDresden, Germany